HBOT for Crohn's Disease & Inflammatory Bowel Disease | NorCal Hyperbarics Concord, CA

Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis (UC) — chronic inflammatory conditions of the gastrointestinal tract that are driven by dysregulated immune responses to the gut microbiome in genetically susceptible individuals. Crohn's disease can affect any part of the GI tract from mouth to anus, with transmural (full-thickness) inflammation that produces strictures, abscesses, and fistulae. Ulcerative colitis is limited to the colon and rectum, with superficial mucosal inflammation that causes bloody diarrhea and urgency. An estimated 3.1 million Americans live with IBD, with peak onset between ages 15 and 35.

Despite significant advances in biologic therapy (anti-TNF agents, vedolizumab, ustekinumab, JAK inhibitors), a substantial proportion of IBD patients — particularly those with complex Crohn's disease — experience incomplete response, loss of response over time, or are unable to tolerate available biologics. For these patients, and for acute severe flares requiring hospitalization, additional therapeutic options are critically needed. HBOT represents a mechanism of action entirely distinct from immunosuppression, making it a potentially valuable adjunct particularly for biologic-refractory patients.

The Bay Area's young, health-aware professional population includes significant numbers of IBD patients who are active in their own care and research-literate enough to pursue evidence-based adjunctive therapies. Contra Costa County's regional medical centers including John Muir Health have active gastroenterology programs whose patients may benefit from HBOT as a component of multidisciplinary IBD management.

The role of mucosal hypoxia in IBD pathophysiology has become increasingly recognized as a therapeutic target. Inflamed intestinal tissue is profoundly hypoxic: the combination of increased metabolic demand from activated immune cells, edema-induced vascular compression, and thrombosis in inflamed mucosal vessels creates an oxygen-deprived environment that impairs epithelial repair, promotes anaerobic bacterial overgrowth, and sustains the inflammatory cycle. HBOT directly corrects this hypoxia.

At 2.0 to 2.5 atmospheres of 100% oxygen, HBOT delivers dissolved oxygen concentrations sufficient to restore oxygenation in hypoxic intestinal mucosa. This elevated oxygen environment directly reduces the activation of NF-κB and other hypoxia-induced pro-inflammatory pathways, supports the restoration of the intestinal epithelial barrier through fibroblast activation and tight junction protein upregulation, and reconstitutes the oxidative killing capacity of mucosal immune cells while simultaneously suppressing the systemic inflammatory cytokine storm. HBOT is also directly bactericidal to some of the anaerobic organisms (including adherent-invasive E. coli in Crohn's) that colonize disrupted intestinal mucosa and perpetuate inflammation.

The clinical evidence is most robust for Crohn's disease, with multiple series documenting 78 to 88% response rates in active disease. Perianal fistulizing Crohn's disease — one of the most difficult management challenges in all of gastroenterology, often refractory to both biologics and surgery — shows particularly promising results with HBOT in multiple published series, suggesting that the tissue hypoxia in fistula tracks may be a key driver of their failure to heal. UC in acute severe flare, including steroid-refractory presentations approaching the colectomy threshold, has also responded to HBOT in case series and small controlled trials. Dr. Toth coordinates HBOT closely with patients' gastroenterologists and colorectal surgeons throughout the Bay Area.